

NDA 20-333/S-002

Roberts Laboratories Inc.  
Attention: Richard J. Raffa  
4 Industrial Way West  
Eatontown, New Jersey 07724-2274

Dear Mr. Raffa:

Please refer to your supplemental new drug application dated December 30, 1997, received January 2, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Agrylin® (anagrelide hydrochloride) Capsules.

We acknowledge receipt of your submissions dated March 2, April 8, June 25, and November 19, 1998.

This supplemental new drug application provides for the use of Agrylin® (anagrelide hydrochloride) Capsules for treatment of patients with thrombocytopenia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-333/S-002." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane

Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a “Dear Health Care Practitioner” letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Ms. Julieann DuBeau, Regulatory Health Project Manager, at (301) 827-7310.

Sincerely,

Lilia Talarico, M.D.  
Director  
Division of Gastrointestinal and Coagulation Drug  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

Enclosure